898 results on '"Leighl, N."'
Search Results
2. Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation
3. 65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy
4. OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
5. EP12.03-02 Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA)
6. Survival Outcomes of Extensive Stage Small Cell Lung Cancer Patients Treated with Consolidative Thoracic Radiotherapy at a Tertiary Cancer Center
7. 170P Preliminary results from LUMINANCE: A phase IIIb, single-arm study of 1L durvalumab (D) + platinum-etoposide (EP) for patients with extensive-stage SCLC (ES-SCLC)
8. 27P Amivantamab versus alternative real-world anti-cancer therapies in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations in the US and Europe
9. Impact of early palliative care on caregivers of patients with advanced cancer: cluster randomised trial
10. Negative Predictive Value of Pre-diagnostic Plasma ctDNA Testing in Patients With Suspected Lung Cancer
11. Longitudinal Plasma ctDNA Testing in Resected Early-Stage NSCLC
12. 398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure
13. 358P Intracranial metastatic disease (IMD) burden and management of patients with small cell lung cancer (SCLC): A population-based analysis of 8705 patients
14. 147TiP Exactis-01 - Clinical utility of returning liquid biopsy NGS results in NSCL cancer patients: A Canadian trial through the Exactis Network
15. EP08.02-082 Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
16. 1151P Evolution of biomarker testing among non-squamous/non-small cell lung cancer (NSCLC) patients (Pts) and impact on turnaround times (TAT)
17. 1144P Clinical outcomes of NSCLC patients (pts) who had brain-only metastasis at time of stage IV diagnosis, by presence versus absence of EGFR/ALK mutations
18. 1112P Real-world treatment (tx) patterns and outcomes based on PD-L1 status in tx-naive patients (pts) with METex14 advanced non-small cell lung cancer (aNSCLC)
19. EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer
20. 1111P Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global Expanded Access Program (EAP)
21. EP08.02-080 EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting
22. 776P Early mortality in patients with cancer treated with immunotherapy in routine practice
23. EP08.02-173 Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings
24. EP02.04-009 Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC
25. 1191TiP Nivolumab-ipilimumab with cfDNA-guided treatment intensification as a chemotherapy-sparing strategy in metastatic non-small cell lung cancer (ATLAS)
26. 1058P Non-smokers with squamous lung cancers have a high incidence of HHV infections, DDR gene alterations and good prognosis
27. OA13.04 Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study
28. EP08.02-016 Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs
29. EP14.05-009 LUMINANCE: A Phase IIIb Study of Durvalumab + Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)
30. 1202TiP Evolution of the tumor immune microenvironment in hepatocellular carcinoma (HCC) and non-squamous non-small cell lung cancer (NSCLC) with liver metastases treated with atezolizumab and bevacizumab (INTEGRATE)
31. EP08.01-067 Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC
32. EP03.01-002 Co-occurring Mutations, Smoking Status and Prognosis of Early-stage Resected NSCLCs with EGFR Mutations
33. Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer
34. Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma: Topic: Medical Oncology: OA03.06
35. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
36. 20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)
37. OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer
38. FP12.07 Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients
39. P45.05 Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival
40. OA08.04 Validation of Scalable, Automated Data Extraction in an Advanced Lung Cancer Patient Population
41. P59.17 EGFR Mutation Status, Liver Metastasis, and Overall Survival in Advanced Lung Adenocarcinoma Patients
42. P45.09 Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada
43. FP12.01 PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC
44. MA12.03 A Thoracic Cancers International COVID 19 Collaboration Survey on Patients’ Perceptions of COVID-19 (Teravolt-Paper)
45. FP04.01 Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907
46. P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?
47. FP01.03 Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC
48. P45.07 Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC
49. MA08.02 Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort
50. 531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.